Novel immunotherapy strategies for hepatobiliary cancers

Thomas T. Deleon, Yumei Zhou, Bolni Nagalo, Raquel T. Yokoda, Daniel Ahn, Ramesk K Ramanathan, Marcela A. Salomao, Bashar A. Aqel, Amit Mahipal, Tanios Bekaii-Saab, Mitesh J Borad

Research output: Contribution to journalReview article

Abstract

Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.

Original languageEnglish (US)
Pages (from-to)1077-1091
Number of pages15
JournalImmunotherapy
Volume10
Issue number12
DOIs
StatePublished - Sep 1 2018

Fingerprint

Immunotherapy
Neoplasms
Oncolytic Virotherapy
Therapeutics
T-Cell Antigen Receptor
T-Lymphocytes
Proteins

Keywords

  • biliary tract cancers
  • CAR-T-cell therapy
  • hepatocellular carcinoma
  • immunotherapy
  • oncolytic virotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Novel immunotherapy strategies for hepatobiliary cancers. / Deleon, Thomas T.; Zhou, Yumei; Nagalo, Bolni; Yokoda, Raquel T.; Ahn, Daniel; Ramanathan, Ramesk K; Salomao, Marcela A.; Aqel, Bashar A.; Mahipal, Amit; Bekaii-Saab, Tanios; Borad, Mitesh J.

In: Immunotherapy, Vol. 10, No. 12, 01.09.2018, p. 1077-1091.

Research output: Contribution to journalReview article

Deleon, Thomas T. ; Zhou, Yumei ; Nagalo, Bolni ; Yokoda, Raquel T. ; Ahn, Daniel ; Ramanathan, Ramesk K ; Salomao, Marcela A. ; Aqel, Bashar A. ; Mahipal, Amit ; Bekaii-Saab, Tanios ; Borad, Mitesh J. / Novel immunotherapy strategies for hepatobiliary cancers. In: Immunotherapy. 2018 ; Vol. 10, No. 12. pp. 1077-1091.
@article{4db1048f115f40dd8bf1f7663153c00a,
title = "Novel immunotherapy strategies for hepatobiliary cancers",
abstract = "Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.",
keywords = "biliary tract cancers, CAR-T-cell therapy, hepatocellular carcinoma, immunotherapy, oncolytic virotherapy",
author = "Deleon, {Thomas T.} and Yumei Zhou and Bolni Nagalo and Yokoda, {Raquel T.} and Daniel Ahn and Ramanathan, {Ramesk K} and Salomao, {Marcela A.} and Aqel, {Bashar A.} and Amit Mahipal and Tanios Bekaii-Saab and Borad, {Mitesh J}",
year = "2018",
month = "9",
day = "1",
doi = "10.2217/imt-2018-0024",
language = "English (US)",
volume = "10",
pages = "1077--1091",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - Novel immunotherapy strategies for hepatobiliary cancers

AU - Deleon, Thomas T.

AU - Zhou, Yumei

AU - Nagalo, Bolni

AU - Yokoda, Raquel T.

AU - Ahn, Daniel

AU - Ramanathan, Ramesk K

AU - Salomao, Marcela A.

AU - Aqel, Bashar A.

AU - Mahipal, Amit

AU - Bekaii-Saab, Tanios

AU - Borad, Mitesh J

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.

AB - Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.

KW - biliary tract cancers

KW - CAR-T-cell therapy

KW - hepatocellular carcinoma

KW - immunotherapy

KW - oncolytic virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85052951395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052951395&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0024

DO - 10.2217/imt-2018-0024

M3 - Review article

VL - 10

SP - 1077

EP - 1091

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 12

ER -